Investors have been left with mixed emotions regarding the stock price performance over the year, as it’s been a mixed bag. Year to date metric has recorded a loss of -5.30%.However, over the last six months, we can see a weaker performance of 9.35%. Over the last 30 days, the price of ALLO has leaped by -29.14%. And in the last five days, it has fallen by -13.39%.
Allogene Therapeutics Inc’s stock has seen a rocky market performance. The company’s stock achieved a 1-year high of $6.89 on 05/15/23, and the lowest price during that time was $2.23, recorded on 12/01/23.
52-week price history of ALLO Stock
The history of a stock’s 52-week high and low prices can provide important information about its current state and future potential. Allogene Therapeutics Inc’s current trading price is -55.88% away from its 52-week high, while its distance from the 52-week low is 36.32%. The stock’s price range for this period has been between $2.23 and $6.89. The Healthcare sector company’s shares saw a trading volume of about 2.11 million for the day, which was lower than the average daily volume of 2.27 million over the last three months.
The Connection Between Financial Performance and Market Capitalization
Allogene Therapeutics Inc (ALLO) has experienced a quarterly decline of -3.80% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 514.03M.
How Moving Averages and Trading Volume Data Work Together
Based on Barchart.com data, the company’s moving average over the 100-day period was 3.80, with a change in price of +0.76. Similarly, Allogene Therapeutics Inc recorded 2,757,196 in trading volume during the last 100 days, posting a change of +33.33%.
ALLO’s Debt-to-Equity Ratio: A Comprehensive Review
A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for ALLO stands at 0.19. Similarly, the long-term debt-to-equity ratio is also 0.18.
ALLO Stock Stochastic Average
As of today, the raw stochastic average of Allogene Therapeutics Inc over the last 50 days is at 0.36%. This shows a declinee from the raw stochastic average of the previous 20 days, which was recorded at 0.62%. Further, the company’s Stochastic %K and %D values for the last 20 days were 1.00% and 2.96%, respectively.
